Expression of microRNA Potentially Regulated by AhR and CAR in Malignant Tumors of the Endometrium

Ushakov, D. S.; Dorozhkova, A. S.; Babayants, Ekaterina V.; Ovchinnikov, Vladimir; Кушлинский, Д. Н.; Adamyan, L. V.; Gulyaeva, L. F.; Кушлинский, Н. Е.

doi:10.1007/s10517-018-4242-3

Cited by 13 publications

(10 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our literature review identified 30 articles studying the expression pattern of miR in neoplastic endometrial tissue compared to in benign and/or hyperplastic tissues [13,14,23,24,25,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52]. The studies included an average of 45 endometrial tumor samples (minimum 7, maximum 141), with well-defined histological types for 15 studies.…”

Section: Resultsmentioning

confidence: 99%

The Use of microRNAs in the Management of Endometrial Cancer: A Meta-Analysis

Delangle

Foucher

Larsen

et al. 2019

Cancers

View full text Add to dashboard Cite

Introduction: Endometrial cancer (EC) is the most important gynecological cancer in terms of incidence. microRNAs (miRs), which are post-transcriptional regulators implicated in a variety of cellular functions including carcinogenesis, are particularly attractive candidates as biomarkers. Indeed, several studies have shown that the miR expression pattern appears to be associated with prognostic factors in EC. Our objective is to review the current knowledge of the role of miRs in carcinogenesis and tumor progression and their association with the prognosis of endometrial cancer. Materials and Method: We performed a literature search for miR expression in EC using MEDLINE, PubMed (the Internet portal of the National Library of Medicine) and The Cochrane Library, Cochrane databases “Cochrane Reviews” and “Clinical Trials” using the following keywords: microRNA, endometrial cancer, prognosis, diagnosis, lymph node, survival, plasma, FFPE (formalin-fixed, paraffin-embedded). The miRs were classified and presented according to their expression levels in cancer tissue in relation to different prognostic factors. Results: Data were collected from 74 original articles and 8 literature reviews which described the expression levels of 261 miRs in ECs, including 133 onco-miRs, 110 miR onco-suppressors, and 18 miRs with discordant functions. The review identified 30 articles studying the expression pattern of miR in neoplastic endometrial tissue compared to benign and/or hyperplastic tissues, 12 articles detailing the expression profile of miRs as a function of lymph node status, and 14 articles that detailed the expression pattern of miRs in endometrial tumor tissue according to overall survival or in the absence of recurrence. Conclusions: The findings presented here suggest that miR analysis merits a role as a prognostic factor in the management of patients with endometrial cancer.

show abstract

Section: Resultsmentioning

confidence: 99%

The Use of microRNAs in the Management of Endometrial Cancer: A Meta-Analysis

Delangle

Foucher

Larsen

et al. 2019

Cancers

View full text Add to dashboard Cite

show abstract

“…Finally, AhR has been shown to prevent tumor development through the regulation of several tumor suppressor miRNAs in breast cancer [61], prostate cancer [62], and malignant tumors of the endometrium [63].…”

Section: Ahr As a Tumor Suppressormentioning

confidence: 99%

AhR and Cancer: from Gene Profiling to Targeted Therapy

Paris

Tardif

Galibert

et al. 2020

Preprint

View full text Add to dashboard Cite

The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that has been shown to be an essential regulator of a broad spectrum of biological activities required for maintaining the body's vital functions. AhR also plays a critical role in tumorigenesis. Its role in cancer is complex, encompassing both pro- and anti-tumorigenic activities. Its level of expression and activity are specific to each tumor and patient, increasing the difficulty of understanding the activating or inhibiting roles of AhR ligands. We explored the role of AhR in tumor cell lines and patients using genomic data sets and discuss the extent to which AhR can be considered as a therapeutic target.

show abstract

“…This systematic review identified 105 original articles and two literature reviews reporting the expression pattern of miRNAs . Of the 69 articles comparing neoplastic endometrial tissue with the surrounding healthy tissue, 39 were published after October 31, 2018 and were not presented in our previous review [53][54][55][56][57][58][59]94,96,[98][99][100][101][102][103][131][132][133][134]. Overall, the 69 studies included an average of 82 endometrial tumor samples (minimum 4, maximum 579) and 22 healthy endometrial samples (minimum 5, maximum 56).…”

Section: Expression Profile Of Mirnas Of Epigenetic Modifiers Associated With Malignant Endometrial Tissue Compared With Healthy Endometrmentioning

confidence: 99%

MicroRNA as Epigenetic Modifiers in Endometrial Cancer: A Systematic Review

Favier

Rocher

Larsen

et al. 2021

Cancers

View full text Add to dashboard Cite

The objective of this systematic review is to summarize our current knowledge on the influence of miRNAs in the epigenetic deregulation of tumor-related genes in endometrial cancer (EC). We conducted a literature search on the role of miRNAs in the epigenetic regulation of EC applying the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The following terms were used: microRNA, miRNA, miR, endometrial cancer, endometrium, epigenetic, epimutation, hypermethylation, lynch, deacetylase, DICER, novel biomarker, histone, chromatin. The miRNAs were classified and are presented according to their function (tumor suppressor or onco-miRNA), their targets (when known), their expression levels in EC tissue vs the normal surrounding tissue, and the degree of DNA methylation in miRNA loci and CpG sites. Data were collected from 201 articles, including 190 original articles, published between November 1, 2008 and September 30, 2020 identifying 313 different miRNAs implicated in epigenetic regulation of EC. Overall, we identified a total of 148 miRNAs with decreased expression in EC, 140 miRNAs with increased expression in EC, and 22 miRNAs with discordant expression levels. The literature implicated different epigenetic phenomena including altered miRNA expression levels (miR-182, -230), changes in the methylation of miRNA loci (miR-34b, -129-2, -130a/b, -152, -200b, -625) and increased/decreased methylation of target genes (miR-30d,-191). This work provides an overview of all miRNAs reported to be involved in epigenetic regulation in EC including DNA methylation and RNA-associated silencing. These findings may contribute to novel strategies in diagnosis, risk assessment, and treatments aimed at miRNAs, their target genes or DNA methylation.

show abstract

Expression of microRNA Potentially Regulated by AhR and CAR in Malignant Tumors of the Endometrium

Cited by 13 publications

References 13 publications

The Use of microRNAs in the Management of Endometrial Cancer: A Meta-Analysis

The Use of microRNAs in the Management of Endometrial Cancer: A Meta-Analysis

AhR and Cancer: from Gene Profiling to Targeted Therapy

MicroRNA as Epigenetic Modifiers in Endometrial Cancer: A Systematic Review

Contact Info

Product

Resources

About